Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GC503
- Development stage
- Unknown
- Lead developer
- Gracell Biotechnologies
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GC503 is an autologous CAR-T cell therapy developed by Gracell Biotechnologies targeting mesothelin (MSLN), a cell surface protein highly expressed in various solid tumors. The drug was designed as a mesothelin inhibitor, aiming to treat patients with mesothelin-positive solid tumors. It was part of Gracell's early-stage pipeline and reached the discovery phase, with initial investigator-initiated trials (IIT) conducted in China. However, the program has since been discontinued as part of a strategic reprioritization to focus on more advanced or differentiated candidates within Gracell’s portfolio[1][2][3][7].
02
Targets
Mesothelin
Beyond the preview
Go deeper on GC503.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC503.